Press release
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market: Major Trends Reshaping the Future of the Industry
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market
What Will the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Industry Market Size Be by 2025?
The market size for therapeutics and diagnostics of exocrine pancreatic insufficiency (epi) has seen a robust growth in the recent times. The market which was valued at $5.69 billion in 2024, is estimated to escalate to a value of $6.11 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. Factors contributing to the growth observed in the historic period are increased occurrences of associated conditions, advancements in diagnostic tools, progressions in pharmaceutical field, and improvements in global healthcare reach.
What's the Long-Term Growth Forecast for the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Size Through 2029?
The market for therapeutics and diagnostics in exocrine pancreatic insufficiency (epi) is projected to experience robust expansion over the coming years. The expectation is that it will reach "$8.21 billion in 2029 with a compound annual growth rate (CAGR) of 7.7%. The growth during the forecast period is anticipated due to factors such as telemedicine and remote monitoring, data analytics and AI, patient education and support, regulatory modifications and reimbursement policies. The projected period will see major trends like personalized treatment strategies, innovative therapy development, less invasive diagnostic methods, and collaborative care models.
View the full report here:
https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report
What Are the Key Growth Drivers Fueling the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Expansion?
The surge in diabetes cases is predicted to prompt the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. Diabetes is a chronic metabolic disease characterized by a consistent increase in blood sugar levels (hyperglycemia). This condition is due to the body's inability to produce sufficient insulin or fail to use the insulin generated effectively. Treating EPI with pancreatic enzyme replacement therapy (PERT) can enhance nutrient absorption for those suffering from diabetes and EPI, and also assist in better glycemic control. As per the data released by The National Health Service (NHS England) in June 2024, the UK-based publicly funded health system observed an 18% increase in the pre-diabetes cases identified in England, rising to 3,615,330 in 2023 from 3,065,825 in 2022. Remarkably, there was a nearly 25% surge in cases among individuals under 40, rising to 216,440 in 2023 from 173,166 in 2022. Consequently, this rise in diabetes prevalence is propelling the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp
What Are the Key Trends Driving Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Growth?
Companies of significance in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are adopting strategic alliances to improve technological collaboration and broaden their market penetration. A strategic relationship is commonly a cooperative agreement among two or more establishments where they pool their assets, knowledge, and endeavors to realize shared ambitions or aims. As an example, in February 2023, Codexis, Inc., a protein engineering enterprise from the US, and Nestlé Health Science, a Swiss-based nutritional science organization, disclosed preliminary findings from their Phase 1 clinical examination of CDX-7108, a prospective therapy took aim at treating EPI. The outcomes from this Phase 1 evaluation set the foundation for additional probing that could substantialy enhance therapeutic choices for patients coping with EPI.
How Is the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Segmented?
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented -
1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach
2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning
3) By Drug Type: Generic, Branded
4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels
5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users
Subsegments:
1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations
3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12992&type=smp
Which Companies Are Leading the Charge in Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Innovation?
Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.
Which Regions Are Leading the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market in Revenue?
North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12992
This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market: Major Trends Reshaping the Future of the Industry here
News-ID: 4182273 • Views: …
More Releases from The Business Research Company
Proteasome Inhibitors Industry Outlook 2025-2029: Market Set to Cross $3.14 Bill …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Proteasome Inhibitors Market Size By 2025?
The market size of proteasome inhibitors has seen a robust expansion in recent times. The market size, which was $2.01 billion in 2024, is predicted to reach $2.17 billion in 2025, exhibiting a compound annual growth rate (CAGR) of…
Key Factor Supporting Cell Line Development Market Development in 2025: Rising C …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Cell Line Development Market Size By 2025?
The market size for cell line development has expanded swiftly in the preceding years. A surge from $8.21 billion in 2024 to $9.36 billion in 2025 is projected, with a compound annual growth rate (CAGR) of 13.9%. Upsurge…
Rising Bacterial Infections And The Surge In Demand For Carbapenem-Based Antibio …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Carbapenem-Based Antibiotics Market Through 2025?
There has been a consistent growth in the size of the carbapenem-based antibiotics market in the past few years. The market size is predicted to increase from $4.6 billion in 2024 to $4.78 billion in 2025, reflecting…
Emerging Trends to Drive Atherosclerosis Drugs Market Growth at 3.5% CAGR Throug …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Atherosclerosis Drugs Market Size Growth Forecast: What to Expect by 2025?
The market size of atherosclerosis drugs has been expanding progressively over recent years. It is projected to escalate from $49.89 billion in 2024 to $50.91 billion in 2025, representing a Compound Annual Growth Rate (CAGR) of 2.0%. The…
More Releases for EPI
Consumer Electronics Adoption Fuels The Silicon Epi Wafer Market: Core Growth En …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
What Will the Silicon EPI Wafer Industry Market Size Be by 2025?
Over recent years, the market size for silicon EPI wafers has seen considerable growth. Predictions indicate an increase from $1.8 billion in 2024 to $1.92 billion in 2025, representing a compound annual growth rate (CAGR) of 6.8%. Factors contributing to this historical…
Evolving Market Trends In The Silicon EPI Wafer Industry: Next-Generation Silico …
The Silicon EPI Wafer Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Silicon EPI Wafer Market Size During the Forecast Period?
In recent times, the silicon EPI wafer market has witnessed substantial growth. The market size, which stood at $1.8 billion in…
Leading Growth Driver in the Silicon EPI Wafer Market in 2025: Consumer Electron …
What industry-specific factors are fueling the growth of the silicon epi wafer market?
The silicon EPI wafer market is expected to experience significant growth due to the increased use of consumer electronics products. Consumer electronics (CE) refers to electronic devices specifically designed for everyday use by consumers for non-commercial or professional purposes. Silicon wafers, which are semiconductors, are used in the manufacture of microchips and chips for these electronic devices. For…
EPI Invests $1 Million USD in the EPI Data Center Futurist Scholarship Program
Singapore (15 June 2023) - EPI, the global leader in data center training, audit & certification, is proud to announce the launch of the EPI Data Center Futurist Scholarship program, accompanied by a significant investment of one (1) million US-Dollar. This transformative initiative aims to provide aspiring professionals with the resources and support they need to acquire the specialized knowledge and skills necessary for success in the dynamic data…
Epi Wafer Market to Surpass Valuation of US$ 5.8 Bn by 2030 with Rising Demand f …
The global Epi Wafer market is estimated to attain a valuation of US$ 5.8 billion by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 6% during the forecast period, 2021-2031.
The key objective of the TMR report is to offer a complete assessment of the global market including major leading stakeholders of…
Exocrine Pancreatic Insufficiency (EPI) Therapeutics- Pipeline Analysis
Exocrine pancreatic insufficiency (EPI) is the inability of pancreas to produce enough enzymes for the proper breakdown and absorption of nutrients. The common causes of EPI are damage to pancreas, inflammation of pancreas, pancreatic surgery, and inherited disorders like Crohn’s disease and celiac disease.
Download the sample report at: https://www.pharmaproff.com/request-sample/1024
Some symptoms observed during EPI are pain or tenderness in belly, bad-smelling bowel movements, gas, diarrhea and feeling of fullness. EPI…
